MINIREVIEWS


Aminoglycoside-Induced Hearing Loss in Humans. Robert E. Brummett and Kaye E. Fox .......................................................... 797–800

MECHANISMS OF ACTION: PHYSIOLOGICAL EFFECTS

Lincomycin Increases the Half-Life of β-Lactamase mRNA. Osamu Matsushita, Akinobu Okabe, Hideo Hayashi, and Yasuhiro Kanemasa .......................................................... 805–809


Relationship between Intracellular Concentration of S-Adenosylhomocysteine and Inhibition of Vaccinia Virus Replication and Inhibition of Murine L-929 Cell Growth. Masahide Hasobe, James G. McKee, and Ronald T. Borchardt .......................................................... 828–834

Cellular Pharmacology of 2’,3’-Dideoxy-2’,3’-Didehydrothymidine, a Nucleoside Analog Active against Human Immunodeficiency Virus. Hsu-Tso Ho and Michael J. M. Hitchcock .......................................................... 844–849

Effects of a Derivative of Serotonin (Deoxyfructoserotonin) and Other Antileprosy Drugs on Attachment and Uptake of Mycobacterium leprae by Schwann Cells In Vitro. Aniruddha Choudhury, Nerges F. Mistry, and Noshir H. Antia .......................................................... 866–870

Penicillin-Binding Proteins of Haemophilus ducreyi. B. Craig Lee and Larry E. Bryan .......................................................... 983–986

MECHANISMS OF RESISTANCE


Resistance Emerging after Pefloxacin Therapy of Experimental Enterobacter cloacae Peritonitis. Christine Lucain, Patrick Regamey, Francis Bellido, and Jean-Claude Pechère .......................................................... 937–943


SUSCEPTIBILITY

Feeder Layer-Free In Vitro Assay for Screening Antitrypanosomal Compounds against Trypanosoma brucei brucei and T. b. evansi. Ronald Kaminsky and Erich Zweygarth .......................................................... 881–885

Continued on following page
Human Immunodeficiency Virus Inhibition Is Prolonged by 3'-Azido-3'-Deoxythymidine Alternating with 2',3'-Dideoxycytidine Compared with 3'-Azido-3'-Deoxythymidine Alone.  Stephen A. Spector, Daniel Ripley, and Karen Hsia................................................................. 920–923

Antimicrobial Activity of Ro 23-9424, a Novel Ester-Linked Codrug of Fleroxacin and Desacetylcefotaxime.  Ronald N. Jones, Arthur L. Barry, and Clyde Thornsberry................................................................. 944–950


In Vitro Activity of SK&F 104662, a New Glycopeptide Antibiotic.  Joseph D. C. Yao, George M. Eliopoulos, and Robert C. Moellering, Jr. ........................ 965–967

In Vitro Susceptibility of Bordetella parapertussis to Various Antimicrobial Agents.  Mitsuru Watanabe and Yoshiko Haraguchi .................. 968–969

Comparison of the In Vitro Activities of Fenticonazole, Other Imidazoles, Metronidazole, and Tetracycline against Organisms Associated with Bacterial Vaginosis and Skin Infections.  Brian M. Jones, Ian Geary, Margaret E. Lee, and Brian I. Duerden ................................................................. 970–972

EXPERIMENTAL THERAPEUTICS

Prevention of Tubercidin Host Toxicity by Nitrobenzylthioinosine 5’-Monophosphate for the Treatment of Schistosomiasis.  Mahmoud H. el Kouni, Djiby Diop, Patricia O’Shea, Ricarda Carlisle, and Jean-Pierre Sommadossi ...... 824–827

In Vitro and In Vivo Antibacterial Activities of BMY 40062, a New Fluoronaphthyridone.  Joan Fung-Tomc, James V. Desiderio, Yuan H. Tsai, Glenn Warr, and Robert E. Kessler ................................................................. 906–914

Feline Immunodeficiency Virus, a Model for Reverse Transcriptase-Targeted Chemotherapy for Acquired Immune Deficiency Syndrome.  Thomas W. North, Ginnie Lee T. North, and Niels C. Pedersen ................................................................. 915–919

Influence of Etoposide and Cyclophosphamide on the Efficacy of Cloxacillin and Erythromycin in an Experimental Staphylococcal Infection.  Wim Calame, Ron van der Waals, Herman Mattie, and Ralph van Furth. .............................. 980–982

CLINICAL THERAPEUTICS


Continued on following page
Single-Dose Enoxacin Compared with 3-Day Treatment for Urinary Tract Infection. C. I. Backhouse and Julie A. Matthews ................................. 877–880

PHARMACOLOGY

Pharmacokinetics of Subcutaneous Azidothymidine in Rhesus Monkeys. Frank M. Balis, Cynthia McCully, Lauren Gough, Philip A. Pizzo, and David G. Poplack ................................................................. 810–812
Pharmacokinetics of Gentamicin in Neonates on Extracorporeal Membrane Oxygenation. W. Michael Southgate, Joseph T. DiPiro, and Alex F. Robertson ................................................................. 817–819
Dose-Dependent Pharmacokinetics of Mezlocillin in Rats. Gail L. Junghbluth and William J. Jusko ......................................................... 839–843
Pharmacokinetics of Intravenous Cefmetazole with Emphasis on Comparison between Predicted Theoretical Levels in Tissue and Actual Skin Window Fluid Levels. James S. Tan, Sara-Jane Salstrom, Steven A. Signs, Howard E. Hoffman, and Thomas M. File ......................................................... 924–927
Role of Sodium in the Protective Effect of Ticarcillin on Gentamicin Nephrotoxicity in Rats. Akihiro Ohnishi, Tanya D. Bryant, Kieran R. Branch, Ramzi Sabra, and Robert A. Branch ......................................................... 928–932
Sputum Levels of Fluconazole in Humans. P. Ebden, P. Neill, and P. R. Farrow ......................................................... 963–964
Serial Trough and Peak Amikacin Levels in Plasma as Predictors of Nephrotoxicity. Ana Maria Contreras, Gerardo Gamba, Jorge Cortés, Yaffita Santiago, Felipe Nares, Gerardo Jimenez-Sanchez, Juan Bobadilla, Guadalupe López, Alba Valadez, Angeles Espinosa, José Sifuentes, and José Carlos Peña ......................................................... 973–976

LETTER TO THE EDITOR

Antibiotic Treatment of Enterococcal Infection. J. M. T. Hamilton-Miller ...... 989

Date of Issue: 2 June 1989